Search

Search Constraints

You searched for: Author/Creator Berteloot, Patrick

Search Results

1. 2022-RA-1263-ESGO Phase II randomized BGOG-CX3 trial comparing atezolizumab in combination with doxorubicin versus doxorubicin alone in second-line or later recurrent cervical cancer. (20th October 2022)

2. 2022-RA-1473-ESGO Randomized phase II CLIO study on olaparib monotherapy versus chemotherapy in recurrent ovarian cancer – results of the Leuven HRD test. (20th October 2022)

3. 2022-RA-884-ESGO Whole-body diffusion-weighted MRI (WB-DWI/MRI) for the prediction of resectable disease at the time of secondary cytoreductive surgery for relapsed epithelial ovarian cancer. (20th October 2022)

4. Body Mass Index and Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer. (6th July 2020)

5. Diagnostic value of whole body diffusion-weighted MRI compared to computed tomography for pre-operative assessment of patients suspected for ovarian cancer. (September 2017)

6. Does Paclitaxel-Carboplatin Chemotherapy in a Dose-Dense Regimen Enhance Survival of BRCA-Related Ovarian Cancer Patients?. Issue 9 (1st November 2009)

7. Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. Issue 1 (January 2018)

8. Incidence of osteonecrosis of the jaw in patients with bone metastases treated sequentially with bisphosphonates and denosumab. Issue 2 (4th March 2018)

10. The Role of Adjuvant Chemotherapy in Surgical Stages I-II Serous and Clear Cell Carcinomas and Carcinosarcoma of the Endometrium: A Collaborative Study. Issue 2 (1st January 2011)